Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

K. M. Williams; L. W. Ostrow; D. M. Loeb; T. Chung; R. D. Cohn; A. M. Corse; A. L. Mammen; A. R. Chen

doi:10.1038/bmt.2011.164

Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

K. M. Williams, L. W. Ostrow, D. M. Loeb, T. Chung, R. D. Cohn, A. M. Corse, A. L. Mammen, A. R. Chen

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.

Original language	English (US)
Pages (from-to)	731-733
Number of pages	3
Journal	Bone marrow transplantation
Volume	47
Issue number	5
DOIs	https://doi.org/10.1038/bmt.2011.164
State	Published - May 2012

Keywords

CD20, myositits
cGVHD
rituximab

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/bmt.2011.164

Cite this

@article{3b0a5901014747389296d1394fb6d323,

title = "Immunohistochemistry of affected tissue may guide cGVHD treatment decisions",

abstract = "Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.",

keywords = "CD20, myositits, cGVHD, rituximab",

author = "Williams, {K. M.} and Ostrow, {L. W.} and Loeb, {D. M.} and T. Chung and Cohn, {R. D.} and Corse, {A. M.} and Mammen, {A. L.} and Chen, {A. R.}",

year = "2012",

month = may,

doi = "10.1038/bmt.2011.164",

language = "English (US)",

volume = "47",

pages = "731--733",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

AU - Williams, K. M.

AU - Ostrow, L. W.

AU - Loeb, D. M.

AU - Chung, T.

AU - Cohn, R. D.

AU - Corse, A. M.

AU - Mammen, A. L.

AU - Chen, A. R.

PY - 2012/5

Y1 - 2012/5

N2 - Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.

AB - Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.

KW - CD20, myositits

KW - cGVHD

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84860886784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860886784&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.164

DO - 10.1038/bmt.2011.164

M3 - Article

C2 - 21927032

AN - SCOPUS:84860886784

SN - 0268-3369

VL - 47

SP - 731

EP - 733

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 5

ER -

Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this